Deliargyris Efthymios 4
4 · Cytosorbents Corp · Filed Oct 8, 2024
Insider Transaction Report
Form 4
Deliargyris Efthymios
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-10-04+100,000→ 100,000 totalExercise: $1.19Exp: 2034-10-04→ Common Stock (100,000 underlying) - Award
Stock Option (Right to Buy)
2024-10-04+50,000→ 50,000 totalExercise: $1.19Exp: 2034-10-04→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.
- [F2]These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.